通讯作者: 李杰, lijie090715@126.com

DOI：10.12201/bmr.202504.00077

Research Advances in Heart Failure with Preserved Ejection Fraction Complicated by Chronic Kidney Disease

• 摘要：射血分数保留的心力衰竭（heart failure with preserved ejection fraction,HFpEF）与慢性肾脏疾病（chronic kidney disease,CKD）是两类具有共同危险因素和病理生理机制的慢性疾病，二者相互影响，显著增加心血管及肾脏不良结局风险。钠水潴留、神经内分泌激活、慢性炎症、贫血、氧化应激及盐皮质激素受体过度激活等机制共同驱动心肾恶性循环，导致心肌纤维化、心室僵硬度增加及肾脏损伤。近年来，针对HFpEF合并CKD的治疗策略取得重要进展，除了传统的利尿剂以外，SGLT2抑制剂、非甾体类盐皮质激素受体拮抗剂、GLP-1受体激动剂等药物展现出新的治疗前景。本文综述了 HFpEF 合并 CKD 的流行病学、病理生理机制、治疗的最新研究进展，旨在提高临床对这一复杂共病状态的认识与管理水平。

  关键词： 心力衰竭；射血分数保留的心力衰竭；慢性肾脏疾病；心肾综合征；SGLT2抑制剂；综述; ; ; ; ; 

   

  Abstract: Heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD) are two chronic diseases with common risk factors and pathophysiological mechanisms. They interact with each other and significantly increase the risk of adverse cardiovascular and renal outcomes. Mechanisms such as sodium and water retention, neuroendocrine activation, chronic inflammation, anemia, oxidative stress, and excessive activation of the mineralocorticoid receptor jointly drive the vicious cycle of heart and kidney, leading to myocardial fibrosis, increased ventricular stiffness, and renal damage. In recent years, important progress has been made in the treatment strategies for HFpEF combined with CKD. In addition to traditional diuretics, drugs such as SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, and GLP-1 receptor agonists have shown new therapeutic prospects. This article reviews the epidemiology, pathophysiological mechanisms, and the latest research progress in the treatment of HFpEF combined with CKD, aiming to enhance clinical understanding and management of this complex comorbidity.

  Key words: Heart failure; Heart failure with preserved ejection fraction; Chronic kidney disease; Cardiorenal syndrome; SGLT2 inhibitors; Review

  提交时间：2025-04-30

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 蔡杰, 韩陈媛. 某三级医院慢性射血分数降低心力衰竭住院患者指南导向药物应用分析与评价. 2025. doi: 10.12201/bmr.202507.00076

  郑洁, 张真稳. SGLT2抑制剂对代谢综合征各组分的影响. 2025. doi: 10.12201/bmr.202503.00002

  蔡欣欣, 吴夏阳. SGLT2i治疗心力衰竭的作用机制及研究进展. 2025. doi: 10.12201/bmr.202507.00052

  薛琴丹. 健康素养在慢性心力衰竭患者症状负担与疾病不确定感间的调节效应分析. 2024. doi: 10.12201/bmr.202407.00062

  郑杰媚, 邱小芩, 韦吉思, 丘欣雨, 刘娜, 陈思帆. 慢性心力衰竭患者症状群的范围综述. 2025. doi: 10.12201/bmr.202501.00046

  吴晗, 廖才刚, 杨冯静. 温潜法分期治疗慢性心力衰竭探析. 2025. doi: 10.12201/bmr.202510.00061

  赵家云. 基于循证的营养护理对重症心力衰竭患者疾病转归的影响. 2025. doi: 10.12201/bmr.202503.00018

  李偏, 叶涛, 申娜▲. 高尿酸血症对慢性肾脏病影响的研究进展. 2025. doi: 10.12201/bmr.202503.00045

  马家慧, 王忠. 心力衰竭患者血浆C1q/肿瘤坏死因子相关蛋白6、系统性炎症反应指数水平及临床意义. 2025. doi: 10.12201/bmr.202501.00060

  王敏旭, 帕尔哈提·吐尔逊. 炎症与铁缺乏在心力衰竭患者预后中的预测作用. 2025. doi: 10.12201/bmr.202507.00038

• 序号	提交日期	编号	操作
  1	2025-02-11	10.12201/bmr.202504.00077V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论